Lipid Metabolism in Myotonic Dystrophy
- 322 Downloads
Lipid metabolism abnormality in myotonic dystrophy (DM) was reviewed. Dyslipidemia is frequently seen in patients with DM. Hypertriglyceridemia, low HDL cholesterolemia, high LDL cholesterolemia, and exceeded visceral fat accumulation are common as abnormal lipid metabolism findings in DM. Dyslipidemia is one of risk factors for metabolic syndrome or nonalcoholic fatty liver disease and is closely relevant to insulin resistance. Careful follow-up for dyslipidemia in DM, especially complicated with glucose intolerance, should be required.
KeywordsMyotonic dystrophy Dyslipidemia Lipid metabolism Insulin resistance Glucose intolerance Metabolic syndrome Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis Visceral fat accumulation
This work was partly supported by grants from the Ministry of Health, Labour and Welfare of Japan (H28-Nanchitou(Nan)-Ippan-030) and Japan Agency for Medical Research and Development (AMED) (17ek0109259).
- 1.Harper PS. Myotonic dystrophy. 3rd ed. London: Sunders WB; 2001.Google Scholar
- 2.Jenkins S, editor. Myotonic dystrophies. Epidemiology, diagnosis and therapeutic challenges. New York: Nova Biomedical; 2015.Google Scholar
- 7.Daniele A, De Rosa A, De Cristofaro M, Monaco ML, Masullo M, Porcile C, Capasso M, Tedeschi G, Oriani G, Di Costanzo A. Decreased concentration of adiponectin together with a selective reduction of its high molecular weight oligomers is involved in metabolic complications of myotonic dystrophy type 1. Eur J Endocrinol. 2011;165(6):969–75.CrossRefGoogle Scholar
- 9.Takada H, Kon S, Oyama Y, Kimura T, Nagahata F. The number of CTG repeat is correlated with the accumulation of visceral fat in myotonic dystrophy type 1. Eur J Neurol. 2016;23(Suppl 1):692.Google Scholar
- 21.Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.CrossRefGoogle Scholar
- 31.Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P, ASCOT. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017;389(10088):2473–81.CrossRefGoogle Scholar